Tamoxifen reduces the risk of benign breast disease
Tamoxifen appears to reduce the risk of benign breast disease and may result in fewer biopsies, according to an analysis of data from a major randomized clinical trial of tamoxifen. The findings appear in the February 19 issue of the Journal of the National Cancer Institute.
Tamoxifen was shown in the Breast Cancer Prevention Trial to reduce the incidence of invasive and noninvasive breast cancer by as much as 50% compared to placebo. Other studies have suggested that tamoxifen can also decrease the size of benign breast lesions, which have been associated with a modest increase in the risk for developing invasive breast cancer.
To examine the effect of tamoxifen on the risk of developing benign breast lesions, Elizabeth Tan-Chiu, M.D., of the Cancer Research Network in Plantation, Fla., and her coworkers from the National Surgical Adjuvant Breast and Bowel Project examined the incidence of benign breast disease among 13,203 women treated with either tamoxifen or a placebo as part of the Breast Cancer Prevention Trial. The authors also noted how many biopsies each group of women underwent.
Overall, tamoxifen treatment reduced the risk of benign breast disease by 28%. Women in the tamoxifen group were less likely to develop several types of benign diseases--adenosis, cysts, duct ectasia, fibrocystic disease, hyperplasia, and metaplasia--than women in the placebo group. Tamoxifen therapy also reduced the risk of fibroadenoma and fibrosis--two conditions that often result in biopsies. In fact, women in the tamoxifen group underwent 29% fewer biopsies than women in the placebo group. The authors note that the reduction in risk was mostly seen in women younger than age 50.
The authors conclude that, in the Breast Cancer Prevention Trial, "tamoxifen not only reduced the risk of invasive and noninvasive breast cancer but also reduced the risk of benign breast disease and the morbidity and costs of repeated diagnosis and treatment that are associated with it."
They point out, however, that tamoxifen treatment carries risks, such as stroke and endometrial cancer, and they add that they do not advocate the indiscriminate use of tamoxifen for the treatment of benign breast disease.
Contact: Lori Garvey, National Surgical Adjuvant Breast and Bowel Project, 412-330-4621; fax: 412-330-4645, email@example.com
Tan-Chiu E, Wang J, Costantino JP, Paik S, Butch C, Wickerham DL, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003;95:302–7.
Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.
Linda Wang | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...